Company* | Funding | Amount | Type | Details (Date) |
| | ||||
4SC AG* | European Union | €2.2 | Research grant | To identify and develop new drugs to combat Staphylococcus aureus infections (12/16) |
Aastrom | Defense Advanced Research Projects Agency | $0.897 | Research & | To research and develop a system to engineer human stem cells into an artificial immune system (9/18) |
Acorda | National Institutes | $0.139 | Phase I | To fund research on the potential of antisense technology to be developed into therapeutic agents for the protection and repair of neurons after traumatic spinal cord injury (8/16) |
Acorda | National Institutes | $0.98 | Two-year Phase II SBTTR | To fund collaborative research between Acorda and Allan Bieber and Moses Rodriguez of the Mayo Clinic toward the development of a class of naturally occurring human IgM antibodies for further preclinical testing in multiple sclerosis (12/19) |
ActivX | National Cancer | $0.155 | Phase I | To provide funding to identify key proteins involved in toxicities and adverse events for screening drug compounds (8/1) |
Affymetrix | National Institutes | $4 | Research | To fund continued research on mapping previously hidden transcriptional activity (7/22) |
Allvivo Inc.* | National Science | ND | SBIR | To develop its biomimetic surface technology (9/24) |
Altea | National Institute | $0.106 | Phase I | To develop its patch for delivery of opioid pain medications (8/7) |
Ambion Inc.* | National Institute | $1.6 | Phase II | To develop RNA amplification technologies (8/23) |
Ambion Inc.* | National Institute | $0.221 | Phase I | To further the development of short interfering RNA technologies used to identify human gene function, perform gene structure-function analysis and identify drug targets (9/23) |
Amnis Corp.* | National Cancer | $0.75 | Phase II | To fund development of velocity detection and autofocus technology for a commercial version of Amnis' ImageStream technology (12/2) |
Anadys | German Federal | ND | Three-year | To identify human proteins that are involved in hepatitis C virus translation initiation in cooperation with the European Molecular Biology Laboratory, the Max Planck Institute for Biophysical Chemistry and the University of Gottingen (7/2) |
Applied Gene | National Institutes | ND | Phase I | To fund the development and commercialization of applications of Applied Gene's platform and its associated technologies in molecular diagnostics for infectious disease and cancer (7/9) |
ARC Pharma- | National Research | C$0.225 | Industrial Research Assistance Program grant | To develop ARC's surgical adhesion disease research program (9/24) |
Ardais Corp.* | National Institute | $2 | Advanced Technology Program | To support the development of software technologies to help researchers understand the molecular basis of disease and select the biological targets of greatest clinical relevance for drug discovery (10/8) |
Avant | National Institute | $0.125 | Phase I | To develop its single oral-dose bacterial vectors to immunize people against anthrax (7/2) |
Axxima | German Federal | €1 | Research | To fund a three-year project on new procedures for functional proteome analysis (12/11***) |
BioDelivery | National Institutes | $0.883 | SBIR | To develop an oral formulation of amphotericin B using its nanocochleate delivery technology to be used to treat fungal infections (8/19) |
BioDelivery | National Institutes | $0.6 | SBIR | To develop an oral form of an HIV prophylactic/therapeutic vaccine with its Bioral drug delivery platform (9/12) |
BioForce | National Institutes | $0.5 | Phase II | For the construction and validation of the NanoArrayer instrumentation, the molecular deposition tool for creating ultraminiaturized nanoarrays (7/15) |
BioForce | U.S. Department | ND | Research | To study malignant progression in breast cancer cell lines, and to construct a nanoscale protein array platform and use it as a basic research tool to study alterations in cellular signaling pathways that accompany breast cancer disease progression (12/9) |
BioLife Solutions | National Institutes | $0.158 | SBIR | To gain a more complete understanding of cell death when cells and tissues are stressed by low temperature (10/16) |
Biopure Corp. | U.S. Department | $0.909 | Development grant | To develop its oxygen therapeutic, Hemopure, for use in military trauma applications (9/4) |
Biosearch Italia | Italian Ministry | €6.5 (US$6.4) | Innovation Technology Fund grant | To support development activities of its antibiotics and preparatory research into the processes for their production (9/18) |
Biosyn Inc.* | National Institutes | $10 | Grant | For the development of an HIV- inhibiting compound, Cyanovirin-N, as a microbicide to prevent the sexual transmission of HIV/AIDS (11/4) |
Bolder | National Cancer | $0.1 | SBIR | To support research to attempt to develop longer-acting, more potent forms of human angiostatin using Bolder's targeted protein modification technologies (11/19) |
Bolder | National Cancer | $0.798 | Phase II | To support research to develop long-acting second-generation forms of interleukin-11 to treat chemotherapy-induced thrombocytopenia (12/11) |
Cambria | National Institutes | $2.7 | Cooperative agreement grant | To develop strategies to control the mosquito insect vectors that transmit malaria and other infectious diseases (10/31) |
Capsulation | German Federal | €0.5 | Development grant | To develop artificial cells, which could be used as nanoscale sensors in the field of diagnostics (7/17***) |
Cepheid Inc. | National Institutes | $0.376 | One-year | To develop rapid diagnostic tests for Mycobacteria tuberculosis (8/21) |
Ceretek LLC* | National Cancer | $0.1 | Phase I | To advance certain cancer drug discovery programs that target lysophosphatidic acid receptors (7/22) |
Coley | Defense Advanced | $6 | Development grant | To support development of Coley's CpG immunostimulatory oligonucleotides to enhance anthrax vaccines (12/13) |
Corus Pharma | Cystic Fibrosis | $1.7 | Grant | To support drug formulation, preclinical and Phase I trials of Corus 1020 (inhaled reformulated aztreonam) (10/3) |
Cubist | National Institute | $0.25 | Phase I | To cover six months of research to identify broad-spectrum inhibitors of a bacterial target, Upps (7/30) |
Cyclacel Ltd.* | The UK government | 1.2 | Research | To support research into cancer drugs that disrupt cancer mitosis, the process by which cancer cells divide (10/14) |
Cyntellect Inc.* | National Institutes | $0.5 | SBIR | To study the effectiveness of anti-NFkB thioaptamers as protection against potential bioterrorism pathogen threats (8/27); to develop drug discovery applications on its Laser Enabled Analysis and Processing technology platform (9/20) |
Dendritic | U.S. government | $3.5 | Research | To fund research into the protection against biological warfare; company will research applied dendrimer nanotechnology (10/28) |
Diversa Corp. | Department | $3.3 | Genomes | For research and development directed at the remediation of toxic environments (7/24) |
Echelon | National Institutes | $0.2 | Grant | To develop new Lipid Chip microarrays (11/4) |
EntreMed | FDA's Office of | $0.9 | Research | To support a Phase II Endostatin trial in patients with neuroendocrine tumors (9/30) |
Epicyte | National Institute | $0.6 | Grant | To apply Epicyte's technology to produce on a large scale hybrid antibodies to block the transmission of HIV (10/8) |
EraGen | University of Wisconsin-Madison Medical School and the Wisconsin State Laboratory of Hygiene | ND | Development grant | To develop a genetic test system designed to detect cystic fibrosis (9/12) |
FeRx Inc.* | FDA's Office of | $0.3 | Research grant | To develop MTC-DOX for the treatment of primary liver cancer (10/14) |
Galapagos | Flemish Institute for the | €1.2 | Technology development grant | For bone disease research, specifically in identifying and validating drug targets (11/25) |
Genaera Corp. | U.S. Department of | $1.1 | Research | For the first clinical trial of squalamine in the treatment of prostate cancer; the grant was awarded to Mitchell Sokoloff of the University of Chicago School of Medicine (11/1) |
Gene Network | National Institutes | $0.1 | Phase I | To model colon cancer signaling pathways and to test predictions generated by its in silico model (9/5) |
Gene Network | National Institute | $2 | Advanced Technology Program | To expand the company's in silico cell simulations and to predict the efficacy and toxicity of drug compounds acting on particular targets (10/16) |
Genomatica | U.S. Department | ND | SBIR | To develop a metabolic model of Pseudomonas fluorescens to aid the use of it for toxic waste degradation and improve the bacterium's functionality in agricultural pathogen control (10/17) |
GenomeVision | National Human | $1.6 | Two-year | To further develop genomic technologies by reducing the mini- mum amount of DNA needed for standard instruments to perform analysis using microtiter plates (10/8) |
Genteric Inc.* | National Institutes | ND | Phase I | To evaluate the use of DNA vaccination to the salivary glands for eliciting mucosal and systemic immune responses (10/1) |
Geron Corp. | National Consortium | $0.8 | Development grant | To develop a telomerase inhibitor for the treatment of multiple types of cancer (9/10) |
Geron Corp. | University of California | ND | Renewed BioSTAR project | To continue research on the use of human embryonic stem cells to derive oligodendrocytes for the treatment of spinal cord and related central nervous system injuries (9/24) |
GlycoFi Inc.* | National Institute | $2 | Grant | To fund a three-year project that has a goal of enabling high-capacity production of biological drugs using GlycoFi's yeast strains (10/9) |
Hematech | U.S. government | $3.3 | Grant | To develop a bovine system for producing human polyclonal antibodies against botulinum neurotoxins (10/30) |
HTS Biosystems | NASA Johnson Space | $0.6 | Phase II | To further the Space Station Cellular Biotechnology Program at NASA, which is developing cell culture systems to conduct microgravity research in cell biology (11/18) |
Illumina Inc. | National Institutes | $9 | Research | For large-scale genotyping aimed at understanding the genetic variations that predispose individuals to common illnesses such as cancer and Alzheimer's disease (10/1) |
Infigen Inc.* | A-T Children's | ND | Grant | To create a pig model of neurodegenerative disease (10/23) |
Inologic Inc.* | National Institutes | $0.097 | SBIR | To study the cellular effects of Inologic's drugs for the treatment of cystic fibrosis (11/6) |
Insightful Corp. | National Institutes | $0.75 | Grant | To build a comprehensive, easy- to-use toolkit that allows researchers to mine genomic data and deliver more precise estimations of genetic parameters used extensively in genetic counseling (7/2) |
Invenux Inc.* | National Institute | $0.085 | Phase I | To develop and validate ADME predictive techniques that will be incorporated into its Evolution Chemistry discovery technology (9/18) |
Ixion | National Institute | $0.505 | Phase II | To fund research titled "M3 Receptor: Diagnostic Marker for Sjogren's Syndrome" (11/19) |
Kensey Nash | National Cancer | $0.1 | SBIR | To begin discovery research on a bioresorbable polymer drug delivery device (10/23) |
Kosan Biosciences | National Cancer | $0.1 | Phase I | To develop economical methods to produce Maytansine analogues for targeted anticancer therapeutics (7/16) |
Large Scale | National Institute | $2 | Advanced Technology Program | To develop a new vaccine discovery and production platform (10/8) |
LaunchCyte | State of Pennsylvania | $0.15 | Opportunity grant | To secure LaunchCyte's endeavors in order to preserve and expand existing industry and attract economic development prospects to Pennsylvania (11/6) |
Lexrite Labs | National Cancer | $0.1 | Phase I | To focus on creating a pretargeted radiotherapy system that uses antibodies and other receptor-based targeting agents for the detection and treatment of cancer (11/5) |
Libraria Inc.* | National Institute | $2 | Research & | To evolve Libraria's Chemical Intelligence Platform, designed to be an integrated drug discovery system intended to streamline and accelerate the identification and synthetic design of new chemical entities (10/9) |
Maxygen Inc. | U.S. Army Medical Research and Materiel Command | $2.4 | Three-year | To develop cross-protective vaccines against three types of encephalitis virus (8/22) |
MelTec GmbH* | German Federal | US | Grant | To further its drug discovery programs and its new approaches to individualized medicine by steering the establishment of Cellect, or cellular eukaryotic proteome-code deciphering technology (7/9) |
Molecular | Department of Energy | ND | SBIR | To fund development of methods for microbial DNA amplification using the firm's multiple displacement amplification technology (11/8) |
Morewood | National Institutes | $0.1 | Phase I | To further develop its Ultra High Throughput Screening platform and to develop a "prostate cancer chip" (11/19) |
Morphotek | U.S. Army | ND | Phase I | To support its program to generate recombinant high- titer strains for the production of therapeutic molecules (7/24) |
Morphotek | Pennsylvania | ND | Opportunity grant | To support the growth of the company's platform and infra- structure for morphogenics (10/1) |
MultiCell | National Institutes | ND | SBIR | To study the production of therapeutic plasma proteins by immortalized, nontumorigenic human hepatocytes (11/4) |
Munich Biotech | European Commission | €1.4 | Grant | To cover costs for a project in the area of antitumor angiogenesis; the work will focus on gene therapy to prevent new blood vessel formation of tumors and to induce apoptosis and necrosis in tumor blood vessels (12/12) |
Myogen | National Heart, | $0.75 | SBIR | For Myogen's drug discovery program aimed at the identification of lead compounds that inhibit MEF2-dependent signaling as a treatment for chronic heart failure (11/7) |
Nanosphere | National Institutes | $1.5 | Development grants | To fund the development of single nucleotide polymorphism molecular diagnostic tests to assess genetic risk factors for hypercoagulation disorders and colorectal cancer (9/17) |
Neurocrine | National Institutes | $1.5 | Phase II | To support development of a screening library of compounds for G protein-coupled receptors (8/13) |
Norzyme | National Institutes | $1.5 | Phase II | To study Levoprin-ZG to aid in the disease management of HIV- AIDS patients (8/14) |
NovaRx Corp.* | National Cancer | $2.7 | Phase II | For a Phase II trial to treat lung cancer using an experimental cancer vaccine, which consists of non-small-cell lung cancer cell lines that have been genetically modified with technology called transforming growth factor-beta antisense (9/9) |
NovaScreen Biosciences | National Institute | $1.1 | Two-year Phase II | To develop a profiling database for cocaine medications (6/28) |
Novozymes | U.S. Department | $2.2 | Grant | For enzyme development and applications research in converting biomass to ethanol (10/28) |
NuGEN | National Institutes | ND | Phase I | To develop a rapid and sensitive assay for the detection of anthrax (8/5) |
Paion GmbH* | The German | €4.9 | Development grant | To develop production capabilities for therapeutic proteins (6/27) |
Panacea | National Cancer | ND | Phase I | To develop a diagnostic test for pancreatic cancer based on Panacea's HAAH oncology program (10/23) |
Panacos | National Institutes | $0.143 | Phase I | To help support Panacos' program to discover drugs that inhibit fusion of respiratory syncytial virus to human cells (8/28) |
Paratek | National Institute | ND | Phase I | For screening tetracycline derivatives for activity against Plasmodium falciparum (9/3) |
Peoples | National Institute | $2 | Advanced Technology Program | To create an instrument to discover all of the disease-causing mutations among the human genome's 40,000 genes (10/9) |
Pharmasset | National Institutes | $0.177 | SBTTR | To research the efficacy of a Pharmasset compound, PTAU, designed to reduce the host toxicity of 5-fluorouracil while enhancing its anticancer activity (9/5) |
Pharmasset | National Institutes | $0.214 | SBIR | To fund research on anti-pox- virus nucleosides (9/18) |
PhytoProtein | Economic Development | ND | Development grant | To develop technology to produce recombinant proteins using plant cells as bioreactors (8/29) |
Progenics | National Cancer | $1 | Phase I | To develop immunotherapies for prostate cancer (10/29) |
Prolx | National Cancer | $2.5 | SBIR | To develop Prolx's HIF inhibitor, PX-478, a small molecule that inhibits a protein known as hypoxia inducible factor-1-alpha (8/6) |
ProteoTech Inc.* | National Institute | $1.2 | Phase II | To fund a two-and-a-half-year drug development program for peptide inhibitors for Alzheimer's disease (8/20) |
Provid | National Institutes | $0.268 | Phase I | To support Provid's infectious disease research program to identify specific inhibitors of bacterial RNA polymerase (7/9) |
PsychoGenics Inc.* | National Institute | $1 | SBIR | To help support the development of SmartCube, a high-throughput system for testing behavior and physiology in live animals (8/28) |
Rubicon | National Human | $0.2 | SBIR | To improve and validate Rubicon's OmniPlex technology as a potential universal solution to increase the speed and efficiency of human DNA analysis for drug development and diagnostics (11/12) |
RxKinetic Inc.* | National Institute | $0.225 | Research | To fund early stage development of an adjuvant/delivery system for anthrax vaccine (9/24) |
Sangamo | National Heart, | $1 | Research | To research the application of Sangamo's zinc-finger DNA- binding transcription factor technology in development of a treatment for sickle-cell disease in collaboration with the University of Alabama (7/24) |
Sangamo | National Cancer | $0.54 | Phase II | For research on the application of Sangamo's zinc-finger DNA- binding protein transcription factor technology to permanent- ly silence the expression of a gene and thus the production of the protein that it encodes (10/29) |
Seattle Genetics | National Cancer | $0.129 | SBIR | To develop anticancer prodrugs that can be activated by tumor- associated enzymes (9/17) |
Stemco | National Institutes | $0.109 | Phase I | To support Stemco's project on the enumeration and isolation of human hematopoietic stem cells (7/23) |
Stemco | State of Florida | $0.18 | State | To transplant stem cell-enriched human umbilical cord blood into a mouse model of amyotrophic lateral sclerosis (8/16) |
Structural | National Institutes | $0.754 | Phase II | For the continued development of an anthrax lethal factor inhibitor (7/16) |
Sunesis | National Institute | $0.6 | Phase I | To develop oral inhibitors of HIV integrase for the treatment of HIV (7/24) |
Surface Logix | National Institute | $6.9 | Advanced Technology Program | To develop carbohydrate-based assays, solid-phase synthesis and surface-based detection methodologies applicable to drug discovery (10/9) |
SurroMed Inc.* | National Institutes | ND | SBIR | To support application of SurroMed's integrated biological marker discovery technologies to the identification of bio- markers to facilitate the early and objective diagnosis of Alzheimer's disease (10/7) |
Synergy | National Cancer | $0.204 | SBIR | For the development of analogues of uroguanylin, and for the cloning, expression and production of uroguanylin and other peptide analogues in E. coli (7/3) |
Vical Inc. | National Institute | ND | One-year SBTTR | To develop DNA vaccines against anthrax (7/3) |
Vion | National Cancer | ND | SBIR | To support preclinical studies related to Vion's Tapet anticancer technology (8/15) |
VistaGen | National Institutes | $0.2 | Phase I | To develop biomathematical systems to analyze data generated from ongoing stem cell-based evaluation of known anticancer drugs (7/9) |
VistaGen | National Institutes | $1.7 | Phase II | To advance the development of clinically predictive assays and tools for development of new drugs designed to be safer and less toxic (9/4) |
Xencor Inc.* | National Institute | $2 | Advanced Technology Program | To support the discovery of safer and more effective protein therapeutics, including the development of Xencor's ImmunoPDA technology (10/9) |
Zonagen Inc. | National Institutes | $0.836 | Phase II | To conduct a primate study of the activity of a compound for endometriosis (7/22) |
Zonagen Inc. | National Institutes | $0.108 | Phase I | To study the potential of Progenta and another analogue to inhibit breast tumor growth (7/29) |
Zonagen Inc. | National Institute | $0.099 | Phase I | To study and characterize the immune response obtained with Zonagen's adjuvant (7/31) |
|
| ||||
TOTAL: $131.657M | ||||
|
| ||||
Notes: | ||||
This chart does not include grants that are tied to agreements between biotech companies and nonprofit institutions. | ||||
* Indicates a privately held company or institution. | ||||
** Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
*** Denotes the date the item ran in BioWorld International. | ||||
ND = Not disclosed; CCAT = Center for Commercialization of Advanced Technologies; SBIR = Small Business Innovation Research; SBTTR = Small Business Technology Transfer Research | ||||
OTC BB = Over-the-Counter Bulletin Board | ||||
